Nuvation Bio (NYSE: NUVB) — Company Overview, News & Financial Data
Nuvation Bio is a biotechnology firm focused on innovative oncology treatments, advancing cancer care through clinical trials.
Nuvation Bio
Nuvation Bio (NYSE:NUVB) is a biotechnology firm engaged in the discovery, development, and commercialization of innovative oncology treatments. With a focus on bringing novel solutions to patients suffering from cancer, Nuvation Bio is actively working on a portfolio of promising projects aimed at addressing some of the most challenging diseases. Their objectives include advancing cancer treatment options through clinical trials, leveraging cutting-edge science to uncover new therapy pathways, and ultimately improving patient outcomes. The company's dedicated team of scientists and researchers are committed to pushing the boundaries of what's possible in cancer care, driven by a passion to make a significant difference in the lives of those affected by this devastating disease.
Snapshot
Operations
Products and/or services of Nuvation Bio
- Development of innovative oncology treatments targeting various cancers, focusing on unmet medical needs.
- Research on bi-specific antibodies aimed at improving the precision and effectiveness of cancer immunotherapies.
- Advancement of small molecule therapeutics designed to inhibit cancer cell proliferation and survival.
- Creation of a novel protein degradation platform to target and destroy cancer-causing proteins.
- Exploration of targeted radiotherapy solutions for precise delivery of radiation to cancer cells, minimizing damage to healthy tissues.
- Investigation into cell therapy techniques for cancer treatment, emphasizing the engineering of immune cells to better recognize and eliminate cancer cells.
Nuvation Bio executive team
- David T. HungFounder, President, CEO & Chairman
- Philippe Pierre SauvageCFO & Principal Financial Officer
- Gary HattersleyChief Scientific Officer
- Moses MakunjeVP of Finance and Principal Accounting & Financial Officer
- David C. HanleyChief Technical Operations Officer
- Robert DeVitaVice President of Corporate Development & Investor Relations
- Stephen DangChief Legal Officer & Corporate Secretary
- Stacy MarkelChief People Officer
- Kerry A. WentworthChief Regulatory Officer
- Colleen SjogrenChief Commercial Officer
Key financials
Reported results for Nuvation Bio, in USD.
- Market cap
- 1.6B
- Revenue (TTM)
- 169.9M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.4
- Dividend yield
- —
- Profit margin
- -88.2%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 62.9M | -213.1M | -204.6M | |
| 7.9M | -592.6M | -567.9M | |
| 0 | -99.8M | -75.8M | |
| 0 | -119.7M | -104.2M |